Molecular Templates, Inc. (MTEM)
USD 0.0
(0.0%)
USD 0.0
(0.0%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | 50.39 Million USD | 321.57% |
| 2022 | 11.95 Million USD | -62.64% |
| 2021 | 31.99 Million USD | 141.38% |
| 2020 | -77.33 Million USD | -149.29% |
| 2019 | -31.02 Million USD | -35.35% |
| 2018 | -22.91 Million USD | -223.76% |
| 2017 | -7.07 Million USD | -585.86% |
| 2016 | 1.45 Million USD | -98.02% |
| 2015 | 73.57 Million USD | 399.76% |
| 2014 | 14.72 Million USD | 17.82% |
| 2013 | 12.49 Million USD | 112.97% |
| 2012 | 5.86 Million USD | 9362.9% |
| 2011 | 62 Thousand USD | 0.0% |
| 2010 | - USD | -100.0% |
| 2009 | 1.44 Million USD | 0.0% |
| 2008 | 1.44 Million USD | 0.28% |
| 2007 | 1.43 Million USD | -1.71% |
| 2006 | 1.46 Million USD | 111.74% |
| 2005 | 690 Thousand USD | 0.0% |
| 2004 | - USD | 0.0% |
| 2003 | - USD | 0.0% |
| 2002 | - USD | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q1 | 9.93 Million USD | 73.26% |
| 2024 Q2 | -504 Thousand USD | -148.62% |
| 2023 FY | 50.39 Million USD | 321.57% |
| 2023 Q3 | 5.29 Million USD | 178.04% |
| 2023 Q1 | 14.58 Million USD | 2754.21% |
| 2023 Q2 | -6.78 Million USD | -146.53% |
| 2023 Q4 | 5.73 Million USD | 8.27% |
| 2022 FY | 11.95 Million USD | -62.64% |
| 2022 Q1 | 6.61 Million USD | -59.08% |
| 2022 Q2 | 2.51 Million USD | -61.94% |
| 2022 Q4 | 511 Thousand USD | 102.88% |
| 2022 Q3 | -17.73 Million USD | -804.53% |
| 2021 FY | 31.99 Million USD | 141.38% |
| 2021 Q2 | -5.99 Million USD | 66.98% |
| 2021 Q3 | -20.5 Million USD | -242.1% |
| 2021 Q4 | 16.16 Million USD | 178.84% |
| 2021 Q1 | -18.14 Million USD | 3.47% |
| 2020 FY | -77.33 Million USD | -149.29% |
| 2020 Q1 | -18.83 Million USD | -58.44% |
| 2020 Q2 | -24.37 Million USD | -29.44% |
| 2020 Q3 | -15.32 Million USD | 37.13% |
| 2020 Q4 | -18.8 Million USD | -22.69% |
| 2019 Q1 | -2.04 Million USD | 41.43% |
| 2019 Q3 | -12.06 Million USD | -139.71% |
| 2019 Q4 | -11.88 Million USD | 1.47% |
| 2019 FY | -31.02 Million USD | -35.35% |
| 2019 Q2 | -5.03 Million USD | -146.55% |
| 2018 Q3 | -6.25 Million USD | 6.83% |
| 2018 FY | -22.91 Million USD | -223.76% |
| 2018 Q4 | -3.48 Million USD | 44.32% |
| 2018 Q1 | -6.45 Million USD | -68.21% |
| 2018 Q2 | -6.71 Million USD | -4.06% |
| 2017 Q2 | 1.76 Million USD | 115.16% |
| 2017 Q1 | 818 Thousand USD | 268.66% |
| 2017 FY | -7.07 Million USD | -585.86% |
| 2017 Q4 | -3.83 Million USD | -104.8% |
| 2017 Q3 | -1.87 Million USD | -206.48% |
| 2016 Q1 | -1.48 Million USD | -102.25% |
| 2016 Q4 | -485 Thousand USD | 78.65% |
| 2016 FY | 1.45 Million USD | -98.02% |
| 2016 Q3 | -2.27 Million USD | -59.81% |
| 2016 Q2 | -1.42 Million USD | 4.05% |
| 2015 Q2 | 3.68 Million USD | -0.03% |
| 2015 FY | 73.57 Million USD | 399.76% |
| 2015 Q4 | 65.87 Million USD | 1690.05% |
| 2015 Q3 | 3.68 Million USD | 0.0% |
| 2015 Q1 | 3.68 Million USD | 0.0% |
| 2014 Q4 | 3.68 Million USD | 0.03% |
| 2014 FY | 14.72 Million USD | 17.82% |
| 2014 Q1 | 3.68 Million USD | 14.6% |
| 2014 Q2 | 3.68 Million USD | -0.03% |
| 2014 Q3 | 3.68 Million USD | 0.0% |
| 2013 FY | 12.49 Million USD | 112.97% |
| 2013 Q1 | 2.92 Million USD | 44.58% |
| 2013 Q2 | 3.18 Million USD | 8.83% |
| 2013 Q3 | 3.18 Million USD | 0.03% |
| 2013 Q4 | 3.21 Million USD | 0.97% |
| 2012 Q1 | 252 Thousand USD | 306.45% |
| 2012 Q3 | 1.79 Million USD | 0.0% |
| 2012 FY | 5.86 Million USD | 9362.9% |
| 2012 Q2 | 1.79 Million USD | 613.1% |
| 2012 Q4 | 2.02 Million USD | 12.47% |
| 2011 FY | 62 Thousand USD | 0.0% |
| 2011 Q4 | 62 Thousand USD | 0.0% |
| 2011 Q1 | - USD | 0.0% |
| 2011 Q3 | - USD | 0.0% |
| 2011 Q2 | - USD | 0.0% |
| 2010 Q4 | - USD | 0.0% |
| 2010 Q1 | - USD | 0.0% |
| 2010 FY | - USD | -100.0% |
| 2010 Q2 | - USD | 0.0% |
| 2010 Q3 | - USD | 0.0% |
| 2009 FY | 1.44 Million USD | 0.0% |
| 2009 Q4 | - USD | 0.0% |
| 2009 Q3 | - USD | 0.0% |
| 2009 Q2 | - USD | 0.0% |
| 2009 Q1 | - USD | -100.0% |
| 2008 FY | 1.44 Million USD | 0.28% |
| 2008 Q3 | 362 Thousand USD | 0.84% |
| 2008 Q4 | 360 Thousand USD | -0.55% |
| 2008 Q2 | 359 Thousand USD | 0.0% |
| 2008 Q1 | 359 Thousand USD | 0.0% |
| 2007 Q3 | 359 Thousand USD | 0.0% |
| 2007 Q4 | 359 Thousand USD | 0.0% |
| 2007 FY | 1.43 Million USD | -1.71% |
| 2007 Q1 | 359 Thousand USD | -6.51% |
| 2007 Q2 | 359 Thousand USD | 0.0% |
| 2006 FY | 1.46 Million USD | 111.74% |
| 2006 Q1 | 359 Thousand USD | 255.45% |
| 2006 Q4 | 384 Thousand USD | 6.96% |
| 2006 Q3 | 359 Thousand USD | 0.0% |
| 2006 Q2 | 359 Thousand USD | 0.0% |
| 2005 Q4 | 101 Thousand USD | -69.49% |
| 2005 Q1 | - USD | 0.0% |
| 2005 Q2 | - USD | 0.0% |
| 2005 FY | 690 Thousand USD | 0.0% |
| 2005 Q3 | 331 Thousand USD | 0.0% |
| 2004 Q4 | - USD | 0.0% |
| 2004 FY | - USD | 0.0% |
| 2004 Q3 | - USD | 0.0% |
| 2003 FY | - USD | 0.0% |
| 2002 FY | - USD | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| America Great Health | 168.58 Thousand USD | -29792.4% |
| Ampio Pharmaceuticals, Inc. | -250 Thousand USD | 20258.0% |
| Aridis Pharmaceuticals, Inc. | - USD | -Infinity% |
| Biora Therapeutics, Inc. | -551 Thousand USD | 9246.098% |
| Bio-Path Holdings, Inc. | -178 Thousand USD | 28411.798% |
| Better Therapeutics, Inc. | -2.72 Million USD | 1946.647% |
| Calithera Biosciences, Inc. | -1.38 Million USD | 3738.628% |
| Comera Life Sciences Holdings, Inc. | 422.71 Thousand USD | -11821.829% |
| Gene Biotherapeutics, Inc. | - USD | -Infinity% |
| eFFECTOR Therapeutics, Inc. | -22.91 Million USD | 319.883% |
| Eloxx Pharmaceuticals, Inc. | - USD | -Infinity% |
| Evelo Biosciences, Inc. | - USD | -Infinity% |
| Evolutionary Genomics, Inc. | -1.02 Million USD | 5033.465% |
| Finch Therapeutics Group, Inc. | -7.09 Million USD | 810.589% |
| Galera Therapeutics, Inc. | -259 Thousand USD | 19557.529% |
| Innovation1 Biotech Inc. | -52.69 Thousand USD | 95729.815% |
| Kiromic BioPharma, Inc. | -2.79 Million USD | 1902.461% |
| Navidea Biopharmaceuticals, Inc. | -119.29 Thousand USD | 42344.017% |
| NexImmune, Inc. | -1.02 Million USD | 5016.72% |
| Orgenesis Inc. | -5.72 Million USD | 980.262% |
| Panbela Therapeutics, Inc. | -25.64 Million USD | 296.495% |
| Point of Care Nano-Technology, Inc. | -4601.00 USD | 1095405.368% |
| PaxMedica, Inc. Common Stock | - USD | -Infinity% |
| Scopus BioPharma Inc. | - USD | -Infinity% |
| Sorrento Therapeutics, Inc. | 29.38 Million USD | -71.487% |
| Statera Biopharma, Inc. | -488.31 Thousand USD | 10420.204% |
| TRACON Pharmaceuticals, Inc. | -232 Thousand USD | 21821.983% |
| Trevena, Inc. | 1.45 Million USD | -3363.574% |
| Vaxxinity, Inc. | -2.23 Million USD | 2355.819% |
| Vaccinex, Inc. | -16 Million USD | 414.89% |
| Vicapsys Life Sciences, Inc. | - USD | -Infinity% |
| Viracta Therapeutics, Inc. | -492 Thousand USD | 10342.886% |
| ZIVO Bioscience, Inc. | 11.61 Thousand USD | -433965.461% |